NAD+ Injections vs. IV vs. Supplements: What Is the Difference?

The difference is mostly about what actually reaches your cells and how much human evidence exists behind each route. Oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are the only forms studied in dozens of randomized human trials, and they do raise blood NAD+ measurably. Intravenous NAD+ delivers the intact molecule into your bloodstream but has one small published pharmacokinetic study and no completed trials showing it improves any health outcome. Injections under the skin or into muscle have the thinnest evidence of all.

What NAD+ is, and why the delivery route matters so much

NAD+ stands for nicotinamide adenine dinucleotide. It is a coenzyme, meaning a helper molecule that dozens of enzymes need in order to work. Your cells use it to carry electrons during energy production, and a second set of enzymes consumes it outright as a raw material.

Three families of enzymes eat NAD+ as fuel: sirtuins, which regulate gene expression; PARPs, which repair damaged DNA; and CD38, an enzyme on the surface of immune and endothelial cells that breaks NAD+ down. Because NAD+ is constantly consumed and rebuilt, your body runs a continuous turnover cycle rather than holding a static reserve.

The route question comes down to chemistry. NAD+ is a large, negatively charged, phosphorylated molecule. A 2024 review in Nature Reviews Molecular Cell Biology states plainly that NAD+ and its biosynthesis intermediates generally cannot passively diffuse across cell membranes and need dedicated transporters to get inside. That single fact drives most of what follows.

The salvage pathway your body actually uses

Most NAD+ in your body is not built from scratch. It is recycled through what biochemists call the salvage pathway: NAD+ is broken down to nicotinamide, nicotinamide is converted back to NMN, and NMN is converted back to NAD+. Nicotinamide riboside feeds into the same loop one step earlier.

This matters because every delivery route ultimately has to hand your cells something that fits into that loop. Isotope tracing work in mice published in Cell Metabolism found that the main route from oral nicotinamide riboside to host NAD+ runs through conversion into nicotinic acid by gut bacteria, not through the intact molecule traveling to your tissues. Human data on that specific step are thinner, but it illustrates how indirect the path is.

What happens when you swallow NAD+ or its precursors

Oral products fall into three groups: NAD+ itself, NAD+ precursors such as NR and NMN, and plain niacin or nicotinamide, which are ordinary B3 vitamins. They behave very differently.

Why swallowing NAD+ itself is an inefficient way to raise NAD+

The 2024 Nature Reviews Molecular Cell Biology review describes the fate of dietary NAD+ directly: phosphorylated nucleotides do not cross cell membranes, so NAD+ in the gut is broken down to nicotinamide riboside or degraded further before uptake, with the majority absorbed as nicotinamide or nicotinic acid.

In other words, an oral NAD+ capsule is an indirect way to deliver niacin building blocks. It may still nudge your NAD+ levels up, because those building blocks re-enter the salvage pathway, but the intact NAD+ molecule on the label is not what gets absorbed. Note the evidence tier: this is a mechanistic statement from a scientific review, not the result of a human absorption study of NAD+ capsules. There are no large randomized trials of oral NAD+ itself comparable to the trials of NR and NMN.

Oral nicotinamide riboside: the best-documented route

NR is the most studied NAD+ precursor in humans. A 2016 study in Nature Communications first mapped its pharmacokinetics: in a single individual taking 1,000 mg daily for a week, blood cellular NAD+ rose about 2.7-fold after one dose, and a formal crossover study in 12 healthy adults aged 30 to 55 confirmed dose-dependent increases at 100, 300, and 1,000 mg.

The larger confirmation came in 2019. In a randomized, double-blind, placebo-controlled trial of 140 overweight but otherwise healthy adults (35 per group, eight weeks), daily doses of 100, 300, and 1,000 mg of NR raised whole blood NAD+ by roughly 22 percent, 51 percent, and 142 percent respectively within two weeks, and the increases held for the rest of the study. There were no reports of flushing and no significant difference in adverse events versus placebo.

Target engagement is therefore well established for oral NR. Whether that translates into benefit is a separate question, covered below.

Oral nicotinamide mononucleotide: newer, and now legal again as a supplement

NMN sits one step closer to NAD+ in the salvage pathway. A Japanese single-dose safety study in 10 healthy men, published in 2020, used 100, 250, and 500 mg with no significant changes in vital signs or lab values, and a 2023 multicenter trial in GeroScience randomized 80 healthy middle-aged adults to placebo or 300, 600, or 900 mg daily for 60 days. Blood NAD+ rose significantly in all three NMN groups, highest at 600 and 900 mg, with no safety signals over that period.

A 2022 trial in npj Aging gave 250 mg of NMN daily to older men for 6 or 12 weeks. Blood NAD+ rose, gait speed and left grip performance showed nominally significant improvements that the authors themselves flagged as needing confirmation in larger studies, and body composition did not change.

How big are the clinical effects of oral precursors?

Modest at best, and inconsistent. The single most cited positive result is a 2021 Science trial in 25 postmenopausal women with prediabetes who were overweight or obese: 250 mg of NMN daily for 10 weeks improved insulin-stimulated glucose disposal in muscle by about 25 percent. In the same trial, muscle NAD+ content itself did not change, insulin sensitivity in the liver and fat tissue was unaffected, and NMN did not reduce circulating insulin levels or liver fat.

Pushing against that, a 12-week randomized trial in 40 obese, insulin-resistant men used 1,000 mg of NR twice daily and found no improvement in insulin sensitivity, endogenous glucose production, resting energy expenditure, lipolysis, or body composition. Safety bloodwork was normal.

A 2026 systematic review in Ageing Research Reviews identified 113 eligible studies, including 33 human intervention studies. Its summary is the honest one: oral NR and NMN consistently hit their biochemical target and were generally well tolerated over weeks to months, but effects on functional, metabolic, and vascular outcomes were heterogeneous and often null. A 2026 meta-analysis of 15 randomized NMN trials in Nutrients found no significant effects on body weight, BMI, fasting glucose, HbA1c, lipids, or systolic blood pressure, with a small decrease in diastolic blood pressure.

What intravenous NAD+ actually delivers

IV NAD+ bypasses the gut entirely, which is the whole marketing premise. It does put the intact molecule into your bloodstream. What it does after that is much less clear than the sales pitch suggests.

The one published pharmacokinetic study

A 2019 pilot study in Frontiers in Aging Neuroscience gave 750 mg of NAD+ as a six-hour intravenous infusion to 8 healthy men aged 30 to 55, with 3 men receiving saline. The result was counterintuitive: no change in plasma NAD+ or its metabolites appeared for the first two hours. The infused NAD+ was being cleared from plasma as fast as it went in.

By the six-hour mark, plasma NAD+ was up about 398 percent over baseline, with nicotinamide up about 409 percent and methylnicotinamide also sharply higher. The urinary NAD+ excretion rate rose about 538 percent. No adverse events occurred during the infusion, and small shifts in liver enzymes were judged not clinically significant by the authors.

That is essentially the entire published human pharmacokinetic literature on IV NAD+: 11 men, one day, one dose, no clinical outcomes. The study was run at, and partly funded by an affiliate of, a clinic that sells NAD+ infusions. It tells you the molecule is metabolized quickly and that a good deal ends up in urine. It does not tell you that an infusion repairs anything.

What an NAD+ infusion tends to feel like

This is the part most people are unprepared for. A 2026 retrospective pilot published in Frontiers in Aging reviewed records from a commercial wellness clinic where 6 clients received 500 mg of IV NAD+ and 8 received 500 mg of IV nicotinamide riboside, each in 500 mL of saline daily for four days, with clients controlling their own drip rate.

All 6 people in the NAD+ group reported moderate to severe abdominal cramping, diarrhea, nausea, vomiting, increased heart rate, throat pain, congestion, and chest pressure during the infusion. Symptoms resolved when the infusion finished. The NAD+ group averaged 97 minutes per infusion versus 37 minutes in the NR group, because people slowed the drip to tolerate it.

Read that study with its limits in mind: it was retrospective, tiny, unblinded, had no placebo arm, was funded by the clinic chain, used NR donated by its manufacturer, and all seven authors worked for the clinic company. Six people is far too few to estimate how often these symptoms occur. It is not proof that NR is superior. It does corroborate what infusion clinics describe informally, which is that fast NAD+ infusions are physically unpleasant and that the drip rate is the main lever.

What IV NAD+ has not been shown to do

The 2026 systematic review searched the literature through October 2025 and found no eligible outcome trials evaluating intravenous or intramuscular NAD+ itself for anti-aging or wellness indications. One nonrandomized intravenous NMN study met inclusion criteria, contributing short-term safety and biomarker data only, and the IV NAD+ pharmacokinetic pilot was classed as contextual evidence rather than outcome evidence.

So claims that IV NAD+ improves energy, focus, addiction recovery, athletic recovery, or biological age are not currently supported by controlled human trials. They may be true. They have not been tested in a way that can distinguish them from placebo, and infusion settings produce strong placebo effects.

There is also a theoretical concern worth knowing. The 2024 Nature Reviews Molecular Cell Biology review notes that a sustained increase in circulating adenosine, a breakdown product of infused NAD+, is a potential source of detrimental effects, and that the authors were not aware of scientific literature testing the effects of intravenous NAD+. Adenosine is the molecule that slows heart rate and dilates vessels, which may be part of why rapid infusions feel the way they do.

Subcutaneous and intramuscular NAD+ injections

Injections are marketed as the convenient version: a small volume given under the skin or into muscle, often at home, instead of hours in a chair. Pharmacologically that is plausible, since the drug enters the bloodstream over a longer period, which may soften the infusion reaction.

The evidence base, however, is close to empty. As of September 2026, there is no published randomized trial establishing the pharmacokinetics, efficacy, or clinical benefit of subcutaneous or intramuscular NAD+ in humans. The 2026 systematic review found no eligible intramuscular NAD+ outcome studies. What exists is clinic experience and unpublished reports, which cannot separate a real effect from expectation.

One relevant trial is registered. ClinicalTrials.gov entry NCT06919328 describes a randomized, quadruple-blinded study with a planned enrollment of 70 adults comparing 100 mg of nicotinamide riboside against 100 mg of NAD+ and against a bacteriostatic water placebo, each given by intramuscular injection, subcutaneous injection, or IV push. It is sponsored by a nutraceutical research institute in collaboration with the company that makes the NR product. The record was last updated in April 2025, when it was listed as recruiting, and no results had been posted as of September 2026.

Practical points people report with injections include stinging or burning at the site, redness, and a brief flushing sensation. Because these effects have not been formally tabulated in a published trial, no honest frequency figures exist. If you are weighing an injectable protocol, that absence is itself the most important piece of information. The same caution applies across peptide and injectable therapies marketed for wellness, none of which are FDA-reviewed.

Route by route comparison

One pattern is worth naming. Evidence quality runs in almost exactly the opposite direction from marketing intensity. The route with the most human trials is the cheapest and least dramatic one, and the routes promoted as most powerful are the least studied.

Regulatory status as of September 2026

This is where the three routes diverge legally, and the distinctions are worth understanding before you sign a consent form.

Injectable and IV NAD+ is not an FDA approved drug

As of September 2026, there is no FDA approved NAD+ injection or infusion product. Injectable NAD+ reaches patients either from a compounding pharmacy or from a peptide supplier, and neither source is FDA-reviewed. The FDA states directly that compounded drugs are not FDA approved, which means the agency does not verify their safety, effectiveness, or quality before they are marketed, and the same is true of NAD+ from a peptide supplier. What varies between sources is the testing behind each batch and whether a certificate of analysis exists for it.

NAD+ appears on the FDA's Category 1 list of bulk drug substances nominated for use in compounding under section 503A, in the version updated May 14, 2026. Category 1 means the substance is still under evaluation: nominated with enough supporting information that FDA does not intend to act against compounders using it while the review continues, provided the conditions in FDA's interim guidance are met. Category 1 is not approval, and it is not a finding that the substance works.

Two more details matter. Pharmacies compounding under section 503A are not subject to current good manufacturing practice requirements, while registered outsourcing facilities under 503B are. And FDA has said it will no longer place substances nominated on or after January 7, 2025 into these categories, so the interim policy itself is in transition.

Oral NMN is a lawful supplement again, after a three-year fight

NMN's legal status in the United States flipped twice. In May 2022 FDA acknowledged a supplier's new dietary ingredient notification for NMN, a procedural step that is not a safety finding. Then, in letters beginning October 11, 2022, it told the firms that had filed NMN notifications that NMN was excluded from the definition of a dietary supplement because it had been authorized for investigation as a drug. Two trade groups filed a citizen petition on March 7, 2023, and one of them sued the agency in August 2024, according to trade press reporting.

In its response to that petition, dated September 29, 2025, FDA reversed its position and concluded that NMN is not excluded from the dietary supplement definition, because NMN had been marketed as a supplement in the United States before it was authorized for investigation as a drug. Trade press reported that in December 2025 the agency sent letters confirming the reversal to the two suppliers. As of September 2026, NMN can lawfully be sold as a dietary supplement ingredient in the United States, subject to the new dietary ingredient notification process. Nicotinamide riboside was never in that dispute and has been sold as a supplement for years.

Supplement does not mean FDA approved

Under federal law, FDA does not have the authority to approve dietary supplements before they are marketed. Manufacturers and distributors are themselves responsible for evaluating the safety and labeling of their products, and FDA acts after a product reaches the market. That framework is the backdrop for the quality problem described next.

If you compete in a tested sport

NAD+ is not itself a prohibited substance, but the route can be. Under anti-doping rules explained by the U.S. Anti-Doping Agency, intravenous infusions or injections of more than 100 mL within a 12-hour period are prohibited at all times, even when the substance infused is permitted, with narrow exceptions for hospital treatment, surgery, and diagnostic procedures. An NAD+ drip mixed in 500 mL of saline, as in the clinic study described above, exceeds that limit several times over. Confirm current rules with your sport's anti-doping authority before any infusion.

Safety, product quality, and what actually goes wrong

With oral precursors, short-term safety looks reassuring in trials. With injectables, the dominant risk is not the molecule. It is what else is in the vial and who is putting it into you.

Contamination and recalls

FDA enforcement records list multiple recalls of compounded NAD+ injection products over the past decade, most for lack of sterility assurance, and at least one for subpotency. In 2025, a compounder recalled NAD+ for injection because of elevated endotoxin levels; FDA classified that recall as Class I on October 21, 2025, the category reserved for products that may cause serious harm or death.

Endotoxins are fragments of bacterial cell walls. They can be present even when a solution is sterile, because killing bacteria does not remove the debris. Injected, they cause fever, violent shaking chills, vomiting, low blood pressure, and in severe cases a sepsis-like picture. In an August 2026 alert about a different injectable ingredient, FDA described at least 30 patients with fever, chills, pain, dizziness, and signs of shock after injections compounded from dietary supplement grade material, and reminded compounders that supplement grade ingredients are not appropriate for injectable drugs.

Seek urgent medical care if, during or after an infusion or injection, you develop shaking chills, a fever, severe vomiting, chest pain, trouble breathing, fainting, or a spreading red and painful area at an injection site. Those are not normal infusion sensations and can signal contamination, infection, or a severe reaction.

Who administers it matters as much as what is in it

In July 2026, a New York television news investigation reported that a 55-year-old man had been charged with reckless endangerment and unauthorized practice after a 27-year-old woman died a little more than an hour after police say he injected her with NAD+ at a Bronx lifestyle center. According to the criminal complaint quoted in that report, he told police he was not a licensed doctor in New York. The medical examiner had not determined a cause of death at the time of reporting. New York's Department of State said it had completed more than 337 inspections of medical spas and shut down 24 by emergency order.

No one can say from the reporting that NAD+ caused that death. What the case does show is the real-world risk profile of injections and infusions given outside licensed medical supervision. If you pursue an infusion or injection, a licensed clinician should be evaluating you, prescribing it, and present while it runs.

Supplement label accuracy is a documented problem

A 2024 analysis in GeroScience tested 18 commercially available NMN supplements by mass spectrometry. Measured content ranged from a small surplus of about 11 percent above the label to minus 100 percent, and three products had no detectable NMN at all. Seven of the 18 came within 10 percent of the label claim. The authors suggested the shortfalls could reflect either breakdown of the ingredient or less being added than claimed.

Practical consequence: with oral products, third-party testing and a verifiable certificate of analysis are worth more than the brand story on the package.

Longer-term unknowns

The honest summary is that nearly all human data runs from a single dose to about six months. Longer-term questions are unresolved. Methylation of nicotinamide consumes S-adenosylmethionine, and depletion of that pool is one proposed mechanism behind liver toxicity from very high dose nicotinamide or nicotinic acid, with the 2024 review noting that nicotinamide should be considered a drug with toxic potential at adult doses above 3 g daily.

Blood levels of methylated nicotinamide breakdown products have also been reported to correlate with major adverse cardiovascular events in humans, a finding that is observational and not proof that supplementation causes harm. Theoretical cancer concerns exist as well, since dividing cells need NAD+, and are discussed alongside the age-related decline question in whether NAD+ falls with age and whether restoring it helps.

Who should be especially cautious

None of this replaces an individual conversation with a clinician who knows your history. These are the situations where that conversation should happen before, not after.

• You are pregnant, trying to conceive, or breastfeeding. NAD+ precursors have not been studied for safety in pregnancy, and injectable NAD+ has not been studied at all.
• You have an active or recent cancer diagnosis. Rapidly dividing cells depend on NAD+, the interaction between NAD+ boosting and tumor biology is unsettled, and this should be your oncologist's call.
• You have liver disease or elevated liver enzymes, given what is known about high dose B3 compounds and liver stress.
• You have kidney disease, since NAD+ metabolites are cleared in urine and dosing in reduced kidney function has not been characterized.
• You have a heart rhythm disorder or low blood pressure, because of the chest pressure and heart rate changes reported during infusions.
• You are taking niacin or high dose nicotinamide for another reason, to avoid stacking B3 compounds without your prescriber's knowledge.
• You compete in a drug-tested sport, because of the infusion volume rule described above.

Myths and realities

Myth: IV delivery means 100 percent bioavailability, so it must work better

Bioavailability describes how much of a dose reaches the bloodstream, not how much reaches the inside of your cells or does anything useful once there. In the 2019 infusion pilot, plasma NAD+ did not budge for two hours while the infusion ran, and urinary NAD+ excretion rose about 538 percent by six hours. A meaningful fraction of an infusion is cleared or excreted rather than used.

Myth: NAD+ therapy is proven to reverse aging

In rodents, NAD+ augmentation frequently improves metabolic, mitochondrial, and functional measures. In humans, it reliably raises NAD+ in blood and often in tissue, and then mostly fails to move the clinical outcomes people care about. That gap between animal and human results is the central finding of this field so far, not a footnote to it.

Myth: the burning sensation means it is working

The cramping, nausea, and chest pressure during a fast NAD+ infusion have no established relationship to benefit. They track infusion rate, which is why clients in the 2026 retrospective slowed their drips and took nearly an hour longer per session than the NR group. Discomfort is a tolerability problem to manage, not a signal of efficacy.

Reality: NAD+ boosting has produced some real, narrow findings

A 28-day randomized trial of a crystalline NMN formulation in 30 overweight or obese adults aged 45 and over found significantly greater reductions in total and LDL cholesterol, body weight, and diastolic blood pressure versus placebo, while muscle strength, aerobic capacity, insulin sensitivity, and liver and abdominal fat did not change. A 2018 crossover trial of 1,000 mg of NR daily in 24 healthy adults aged 55 to 79 raised NAD+ in blood cells by about 60 percent, with a 3.9 mmHg drop in systolic blood pressure that was not statistically significant after correction. These are small, short signals worth following, not settled conclusions.

How to think about choosing a route

The framing that actually helps is to ask what you want and what evidence would have to exist for a given route to deliver it. Nobody can give you a NAD+ level target worth treating, because no trial has shown that a specific blood NAD+ number predicts how you feel.

1. Name the outcome. Energy, sleep quality, recovery, insulin sensitivity, and cognition are different endpoints with different, mostly thin, evidence. A vague goal cannot be evaluated later.
2. Ask what the best study of that outcome by that route actually found, including how many people were in it and how long it ran.
3. Rule out the ordinary explanations first. Anemia, thyroid disease, sleep apnea, depression, medication effects, and iron or B12 deficiency cause the fatigue that sends most people to NAD+ clinics, and all are testable.
4. Weigh what each route has and what it lacks. Oral precursors have the most trial data for raising blood NAD+ and the fewest procedural risks. Injections and infusions deliver the intact molecule but have little published human data and depend on the quality of the source. No route has been shown to improve energy or function against placebo. Which trade-off fits you is a conversation with a physician about your goals, the cost, and how you will be monitored.
5. Set a review date and a stopping rule in advance, with an objective measure where one exists, so that the decision to continue is not made purely on momentum.

Rx2BFIT offers NAD+ by injection, not by IV infusion, and does not use a compounding pharmacy. Its NAD+ comes from a supplier whose batches are tested by an independent laboratory for identity and purity, with a certificate of analysis on file, and is reconstituted in the office under Dr. Patel's supervision. It is not an FDA-approved product, and the thin human evidence is part of what Dr. Patel reviews with every patient before starting.

If you are already discussing a supervised protocol, the general overview of NAD+ therapy covers how it is typically delivered in clinical practice, and the broader healthy aging and wellness context explains where it sits among other options.

Questions worth asking your prescriber

• Which specific product and route are you recommending, and is it an FDA approved drug, a preparation from a compounding pharmacy or a peptide supplier, or a dietary supplement?
• If it is not FDA approved, who makes or supplies it, is that a 503A pharmacy, a 503B outsourcing facility, or a peptide supplier, and can I see a certificate of analysis from an independent laboratory, including identity, purity, and endotoxin testing?
• What outcome are we aiming for, how will we measure it, and at what point would you tell me it is not working?
• What human evidence supports this route specifically, as opposed to oral precursors or animal studies?
• What side effects should I expect during an infusion, what is the plan if I get chest pressure or severe cramping, and who is present while it runs?
• How does this interact with my current medications and conditions, including my liver and kidney function?
• How does this route compare with an oral precursor for my goal, in evidence, cost, and risk?

A clinician who answers those plainly, including the parts where the honest answer is that nobody knows, is giving you the information you need. Marketing language about cellular recharging is not a substitute for it.

This is general information, not medical advice. Whether a treatment is right for you is determined by a licensed provider after an evaluation.